Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Grants and contracts	$ 156,042	$ 197,919
Operating expenses:
Research and development	218,208	513,421
General and administrative	382,166	474,670
Total operating expenses	600,374	988,091
Loss from operations	(444,332)	(790,172)
Other income (expense):
Interest and other income (expense)	2,900	(7,648)
Foreign exchange gain (loss)	393	(671)
Change in value of warrant liability	(160,689)	(94,821)
Total other income (expense)	(157,396)	(103,140)
Net loss	(601,728)	(893,312)
Net loss attributable to noncontrolling interests	13,196	20,369
Net loss attributable to Cleveland BioLabs, Inc.	$ (588,532)	$ (872,943)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.05)	$ (0.08)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	11,353,456	11,298,239